Hemispherx Biopharma has reached an agreement with Avrio Biopharmaceuticals to serve as an additional contract manufacturer of Hemispherx’s experimental drug, Ampligen, also known by its generic name rintatolimod. Avrio, an FDA inspected facility, has the capabilities for the compounding and fill/finish of sterile clinical and commercial grade Ampligen to satisfy the company’s ongoing domestic clinical studies as well as the recently initiated early access program (EAP) in Europe and Turkey. Thi...